Sebastian Arrizabalaga | Medicine and Health Sciences | Innovative Research Award

Innovative Research Award

Sebastian ArrizabalagaOregon Health & Science University, United States

Sebastian Arrizabalaga
Affiliation Oregon Health & Science University
Country United States
Scopus ID 58650782300
Documents 3
Citations 128
h-index 2
Subject Area Ophthalmology
Event Top Teachers Awards
ORCID 0009-0007-5387-3007

Sebastian Arrizabalaga is a researcher affiliated with Oregon Health & Science University whose work encompasses experimental ophthalmology, retinal disease research, neural stem cell formulations, preclinical models, and quantitative assessment of retinal neuroprotection. His research experience combines laboratory experimentation, animal-based studies, imaging, data analysis, and research project management, supporting translational investigations relevant to retinal disorders and emerging therapeutic strategies. [1][2]

Abstract

Sebastian Arrizabalaga’s academic profile is centered on ophthalmic and retinal research conducted at Oregon Health & Science University. His research activities include evaluating neural stem cell approaches, studying retinal neuroprotection in animal models, and contributing to preclinical investigations involving retinal therapeutics. His technical background includes spectroscopy, chromatography, fluorescence imaging, confocal microscopy, fundus imaging, electroretinography, ocular procedures, and quantitative data analysis. Published work demonstrates participation in studies addressing retinal degeneration, geographic atrophy, and experimental therapeutic development. [1][3][4][5]

Keywords

Ophthalmology; retinal research; neural stem cells; retinal neuroprotection; geographic atrophy; age-related macular degeneration; preclinical research; retinal imaging; electroretinography; animal models; translational medicine; cell-based therapy.

Introduction

Sebastian Arrizabalaga’s research trajectory connects biochemical laboratory training with experimental ophthalmology. After completing a Bachelor of Arts in Chemistry at Reed College, including a thesis examining the functionality of the bacterial tellurium resistance protein TerB, he developed broader expertise in laboratory science, animal experimentation, imaging, and retinal research. His subsequent work at Oregon Health & Science University has focused on experimental approaches relevant to retinal degeneration and therapeutic development. [2][4]

Research Profile

His current research profile includes project and experiment management, preparation of clinical trial approval documentation, laboratory administration, animal colony management, experimental design, and quantitative analysis. Technical competencies encompass UV/Vis spectroscopy, biochemistry, liquid chromatography–mass spectrometry, fluorescence spectroscopy, R programming, immunofluorescence staining, confocal microscopy, optokinetic tracking, fundus imaging, electroretinography, ocular injections and implants, cryosectioning, and microtome-based tissue preparation.[1][2]

  • Retinal and ophthalmic experimental research.
  • Neural stem cell and retinal neuroprotection studies.
  • Preclinical investigation of therapies for retinal degeneration.
  • Quantitative retinal imaging and functional assessment.
  • Laboratory, animal-model, and research-project management.

Research Contributions

A principal contribution of Arrizabalaga’s research record is the quantitative evaluation of retinal neuroprotection produced by distinct human neural stem cell formulations in the Royal College of Surgeons rat model. This work provides experimental evidence for comparing cell-based approaches within a retinal degeneration model and contributes to the broader development of regenerative strategies for retinal disease.[4]

His research also includes work on improving human neural stem cell formulations for potential application to geographic atrophy, a form of advanced dry age-related macular degeneration. In related preclinical research, his collaborative publication record intersects with investigations of retinal gene editing and cell-based therapeutic safety and efficacy, reflecting a translational research pathway from experimental formulation and biological evaluation toward potential clinical applications. [3][5]

Publications

Sebastian Arrizabalaga’s highly relevant publications include a 2023 study quantifying retinal neuroprotection from two human neural stem cell formulations in the RCS rat, followed by a 2024 study addressing improvements to human neural stem cell formulations for geographic atrophy treatment. His collaborative research record also includes work on retinal genome editing using lipid nanoparticles and preclinical studies of GMP-grade retinal pigment epithelial cells for dry age-related macular degeneration, placing his contributions within active translational ophthalmology research. [4][3][5]

  1. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468.
  2. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841.
  3. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535.
  4. Surendran, H., Soundararajan, L., Patlolla, N., Stoddard, J., Arrizabalaga, S., Liu, Z., Gopal, L., Su, X., Ryals, R. C., Battu, R., & Pal, R. (2024). IND-enabling preclinical safety and efficacy studies using GMP-grade human iPSC-derived retinal pigment epithelial cells for treating dry age-related macular degeneration. Investigative Ophthalmology & Visual Science, 65(7), 716.

Research Impact

The research record is relevant to contemporary ophthalmology because retinal degeneration and geographic atrophy require improved methods for protecting or replacing vulnerable retinal cells. Sebastian Arrizabalaga’s participation in studies involving neural stem cell formulations, retinal imaging, functional testing, and preclinical safety and efficacy contributes to the experimental evidence base used to evaluate candidate regenerative and translational therapies. The listed academic profile reports 128 citations across three documents, with an h-index of 2.[1]

Award Suitability

For the Innovative Research Award associated with the Top Teachers Awards, Sebastian Arrizabalaga presents a research profile characterized by laboratory-based ophthalmic investigation, multidisciplinary collaboration, quantitative experimentation, and translational relevance. His work on retinal neuroprotection and neural stem cell formulations provides a coherent research theme connecting experimental models with potential therapeutic development. The combination of technical laboratory expertise, animal-model research, imaging, and publication activity supports consideration within an innovation-focused academic recognition framework.[1][2]

Conclusion

Sebastian Arrizabalaga’s academic record reflects developing expertise in experimental ophthalmology, retinal degeneration research, neural stem cell approaches, and preclinical therapeutic evaluation. His publications and research responsibilities demonstrate engagement with collaborative translational studies addressing retinal neuroprotection and geographic atrophy. Together with a broad technical laboratory skill set and experience managing experimental research activities, these elements form a focused profile in contemporary retinal science. [1]

References

  1. Scopus author profile for Sebastian Arrizabalaga, author identifier 58650782300. https://www.scopus.com/pages/authors/58650782300
  2. ORCID record for Sebastian Arrizabalaga, ORCID 0009-0007-5387-3007. https://orcid.org/0009-0007-5387-3007
  3. Gautam, M., Jozic, A., Su, G. L. N., et al. (2023). Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina. Nature Communications, 14, 6468. https://doi.org/10.1038/s41467-023-42189-3
  4. Arrizabalaga, S., Uchida, N., Curtis, A., Navarro, I., Stoddard, J., Tsukamoto, A., Leng, T., & Ryals, R. C. (2023). Quantification of retinal neuroprotection achieved by two different human neural stem cell formulations in the RCS rat. Investigative Ophthalmology & Visual Science, 64(8), 3841. https://iovs.arvojournals.org/article.aspx?articleid=2788186
  5. Arrizabalaga, S., Uchida, N., Curtis, A. G., Stoddard, J., Sheffield, A., Tsukamoto, A., Leng, T., & Ryals, R. C. (2024). Improving human neural stem cell formulations for geographic atrophy treatment. Investigative Ophthalmology & Visual Science, 65(7), 1535. https://iovs.arvojournals.org/article.aspx?articleid=2796734

Shahinaz Mohamed | Clinical Research | Best Researcher Award

Dr. Shahinaz Mohamed | Clinical Research | Best Researcher Award

Clinical Research Assistant at King Abdullah International Medical Research Center, Saudi Arabia

Dr. Shahinaz F. Mohamed is a highly experienced Medical Writer and Clinical Research Professional with over 12 years of expertise in the medical research field. She holds a Master of Public Health (MPH) from the University of Essex, UK, and is a Certified Clinical Research Associate (CCRA®). With a strong background in clinical trials, medical writing, and regulatory compliance, she has played a pivotal role in developing and managing clinical study protocols, ethical review processes, and scientific publications. Currently, she serves as a Senior Clinical Research Epidemiologist & Medical Writer at King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia. Dr. Mohamed has significantly contributed to peer-reviewed medical journals, showcasing her expertise in public health, evidence-based medicine, and digital health research. Her work in Good Clinical Practice (GCP) training, clinical trial documentation, and regulatory compliance has established her as a key figure in the field of clinical and translational research.

professional profiles📖

ORCID

Google scholar

Education 🎓

Dr. Shahinaz Mohamed has a diverse and well-rounded educational background in public health, clinical research, and medical sciences. She earned her Master of Public Health (MPH) from the University of Essex, UK, in 2019, which provided her with a strong foundation in epidemiology, healthcare policy, and biostatistics. She further enhanced her qualifications by obtaining the Certified Clinical Research Associate (CCRA®) from the USA in 2022, demonstrating her expertise in clinical trials and regulatory compliance. Additionally, she holds a Certified Clinical Research Coordinator (CCRC®) certification from KSA (2013), further establishing her credibility in research methodology and ethical compliance. Her academic journey began with a Diploma of Higher Education in Histopathology from Egypt (2006) and a Bachelor of Veterinary Medicine from Egypt (2004), providing her with deep knowledge in biomedical sciences and medical research. Her comprehensive education has equipped her with the skills necessary for high-quality clinical research and medical writing.

work Experience💼

Dr. Shahinaz Mohamed has been an integral part of the clinical research field for over a decade, primarily serving as a Senior Clinical Research Epidemiologist & Medical Writer at King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia, since 2011. In this role, she has been responsible for developing clinical study protocols, drafting case report forms, and preparing informed consent documents. She has also played a key role in the scientific and ethical evaluation of research proposals for Institutional Review Board (IRB) approval, ensuring compliance with Good Clinical Practice (GCP) and international regulatory standards. Her work includes conducting literature reviews, statistical analysis, and data interpretation for scientific publications, as well as peer-reviewed journal articles and systematic reviews. In addition, she has contributed as a Research Proposal Reviewer and IRB Member, evaluating preclinical and clinical studies and advising investigators on study design, ethical considerations, and publication guidelines.

Research Focus

Dr. Shahinaz Mohamed’s research primarily focuses on infectious diseases, clinical trials, endocrinology, and public health. Her work in infectious disease epidemiology has contributed to the treatment and management of conditions such as Middle East respiratory syndrome (MERS-CoV) and diabetes. She has played a vital role in clinical trials and evidence-based medicine, ensuring the development of robust interventional studies to improve patient outcomes. In the field of endocrinology and metabolic disorders, she has examined the impact of insulin therapy and lipid metabolism in diabetes patients. Additionally, her research extends to medical ethics and GCP compliance, ensuring that clinical trials adhere to the highest ethical standards. She has also been actively involved in digital health and healthcare data analysis, exploring the adoption of personal health records and AI-driven medical research solutions. Her multidisciplinary research contributes to medical advancements and improved healthcare policies.

Awards & Honors🏆 

Dr. Shahinaz Mohamed has been recognized for her significant contributions to clinical research and medical writing through various awards and honors. She earned the prestigious Certified Clinical Research Associate (CCRA®) certification from the USA in 2022, affirming her expertise in clinical trials and research ethics. Additionally, she has been an ICH-GCP Instructor and Certification Trainer, providing Good Clinical Practice (GCP) training for medical professionals. She has been invited as a presenter at Research Methodology & Biostatistics Workshops (Nature Research Academies, 2022) and has served as a Clinical Research Capability Trainer for AstraZeneca in 2022. Her participation as a speaker at Annual Clinical Research Symposiums (KAIMRC, Almoosa Specialist Hospital) further highlights her influence in the medical research community. Recognized for her expertise in Regulatory & Quality Management in Clinical Research (SFDA, FDA compliance), she continues to be a key figure in clinical research training and regulatory affairs.

Skills 🛠️ 

Dr. Shahinaz Mohamed possesses a diverse skill set that allows her to excel in clinical research, scientific writing, and regulatory compliance. She is highly proficient in medical and scientific writing, specializing in manuscripts, abstracts, and study protocols. Her expertise in clinical research methodology and statistical analysis (SPSS, STATA, R) enables her to conduct comprehensive data analysis and interpretation. She is skilled in Institutional Review Board (IRB) submissions and compliance, ensuring ethical approval of clinical trials. Additionally, she is a Good Clinical Practice (GCP) instructor, providing training in research ethics and regulatory compliance. Her proficiency in systematic reviews, manuscript editing, and peer-review coordination makes her a highly sought-after expert in medical publishing. She is also well-versed in digital health research and AI-driven healthcare solutions, contributing to the advancement of innovative medical technologies. With fluency in English and Arabic, she effectively communicates research findings and regulatory guidelines across diverse medical communities.

Conclusion✅

Shahinaz F. Mohamed possesses outstanding qualifications for the Best Researcher Award, given her strong research background, publication record, expertise in clinical research, and commitment to research ethics and training. Her contributions in medical writing, research methodology, and regulatory compliance make her a highly competitive candidate. To further strengthen her profile, she may consider leading independent research projects, contributing to groundbreaking studies, and securing research grants. Nevertheless, her current accomplishments make her a strong contender for this prestigious award. 🚀🏆

📚Publications to Noted

Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Authors: YM Arabi, A Alothman, HH Balkhy, A Al-Dawood, S AlJohani, S Al Harbi, …

Citations: 370

Year: 2018

Molecular Analysis of Congenital Hypothyroidism in Saudi Arabia: SLC26A7 Mutation Is a Novel Defect in Thyroid Dyshormonogenesis

Authors: M Zou, AS Alzahrani, A Al-Odaib, MA Alqahtani, O Babiker, RA Al-Rijjal, …

Citations: 72

Year: 2018

Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting

Authors: MD Reem Alamoudi, MD, MHSc, Maram Alsubaiee, MD, Ali Alqarni, MD, Yousef …

Citations: 39

Year: 2017

Statistical analysis plan for the Pneumatic CompREssion for PreVENting Venous Thromboembolism (PREVENT) trial: a study protocol for a randomized controlled trial

Authors: Y Arabi, F Al-Hameed, KEA Burns, S Mehta, S Alsolamy, M Almaani, …

Citations: 14

Year: 2018

The Dialysis Outcomes and Practice Patterns Study Phase 5 in the Gulf Cooperation Council Countries Design and Study Methods

Authors: Pisoni, Ronald L., BA Bieber, J Al Wakeel, S Al Arrayed, N Alkandari, …

Citations: 11

Year: 2016

Surveillance or no surveillance for deep venous thrombosis and outcomes of critically ill patients: a study protocol and statistical analysis plan

Authors: YM Arabi, KEA Burns, F Al-Hameed, S Alsolamy, M Almaani, …

Citations: 7

Year: 2018

Replacing protein via enteral nutrition in a stepwise approach in critically ill patients: the REPLENISH randomized clinical trial protocol

Authors: YM Arabi, HM Al-Dorzi, M Sadat, D Muharib, H Algethamy, F Al-Hameed, …

Citations: 6

Year: 2023

The effect of intermittent pneumatic compression on deep-vein thrombosis and ventilation-free days in critically ill patients with heart failure

Authors: HM Al-Dorzi, A Al-Dawood, FM Al-Hameed, KEA Burns, S Mehta, J Jose, …

Citations: 5

Year: 2022

Statistical analysis plan for the replacing protein via enteral nutrition in a stepwise approach in critically ill patients (REPLENISH) randomized clinical trial

Authors: YM Arabi, HM Al-Dorzi, O Aldibaasi, M Sadat, J Jose, D Muharib, …

Citations: 3

Year: 2024

Association of advanced lipoprotein subpopulation profiles with insulin resistance and inflammation in patients with type 2 diabetes Mellitus

Authors: A Bakillah, KK Obeid, M Al Subaiee, AF Soliman, M Al Arab, SF Bashir, …

Citations: 3

Year: 2023